The short version of fatty diacid fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Patrick Brenan, Finance Director, Minories Finance Ltd. For services to Banking. Linda Broadhead, Senior Management Pay Band 2, the Employment Service, Department for Education and Employment. Rosemary Anne Brown, Member, Occupational Pensions Board. For services to Pensions Legislation. Barbara Kathleen Bryant, Grade 7, Department of Social Security. Keith Patrick Burke, Managing Director, Dana Spicer Europe Ltd., Dana Corporation. For services to Industry and to the Environment. David Burnett. For services to the Development and Application of Biochemistry to Health Care. William John Burnison. For public service. Derek Harold Calam, Member and Vice Chairman, British Pharmacopoeia Commission. For services to the Control of Medicines. Libby Campbell, Executive Director, Nursing and Quality, West Lothian NHS Trust. For services to Health Care. Dennis Duncan Carmichael, Honorary Treasurer, Lawn Tennis Association. For services to Lawn Tennis. Enid Castle, lately Principal, Cheltenham Ladies' College. For services to Education. Jonathan Joseph Chadwick, Secretary to the Imperial War Museum. Christopher Charlton, Director, Cromford Mill Project, Derbyshire. For services to Conservation. Professor Dennis Child. For services to Deaf People. Edward Samuel Childs, Executive Producer, Carlton UK Television. For services to Television Broadcasting. Brian James Clark, Principal Specialist Inspector, Health and Safety Executive, Department of the Environment. Harold Clarke, District Inspector, Board of Inland Revenue. Seamus Anthony Close. For public service.
Polycyclic aromatic hydrocarbons are tar components produced by pyrolysis in smoldering organic matter and emitted into smoke. Several of these PAH's are already toxic in their normal form, however, many of them can become more toxic to the liver. Due to the hydrophobic nature of PAH's they do not dissolve in water and are hard to expel from the body. In order to make the PAH more soluble in water, the liver creates an enzyme called Cytochrome P450 which adds an additional oxygen to the PAH, turning it into a mutagenic epoxide, which is more soluble but also more reactive. The first PAH to be identified as a carcinogen in tobacco smoke was benzopyrene, which been shown to toxicate into a diol epoxide and then permanently attach to nuclear DNA, which may either kill the cell or cause a genetic mutation. The DNA contains the information on how the cell functions; in practice, it contains the recipes for protein synthesis. If the mutation inhibits programmed cell death, the cell can survive to become a cancer, a cell that does not function like a normal cell. The carcinogenicity is radiomimetic, i.e. similar to that produced by ionizing nuclear radiation. Tobacco manufacturers have experimented with combustionless vaporizer technology to allow cigarettes to be consumed without the formation of carcinogenic benzopyrenes. Acrolein is a pyrolysis product that is abundant in cigarette smoke. It gives smoke an acrid smell and an irritating, tear-causing effect and is a major contributor to its carcinogenicity.
==== Aspartic acid ==== Aspartic acid (aspartate) is one of the most common amino acids in the typical diet. As with methanol and phenylalanine, intake of aspartic acid from aspartame is less than would be expected from other dietary sources. At the 90th percentile of intake, aspartame provides only between 1% and 2% of the daily intake of aspartic acid.
However, Giáp, seeing the weakness of the French position, started moving most of his forces from the De Lattre Line to Điện Biên Phủ. From December 1953 to March 1954, the Việt Minh concentrated more than 40,000 troops to encircle the 15,000 French troops at Điện Biên Phủ. The fight for control of Điện Biên Phủ was the longest and hardest battle for the French Far East Expeditionary Corps and its veterans described the battle as "57 Days of Hell".
Sources: en.wikipedia.org
(2002) subsequently confirmed the same model for hydrogen adsorption on magnesia-supported caesium-ruthenium bimetallic catalysts. Trens et al. (2009) have similarly described CO surface diffusion on carbon-supported Pt particles of varying morphology.
== Caspase-2-PIDDosome == Caspases are a family of cysteine proteases that play key roles in regulating apoptosis and inflammatory responses. These enzymes are divided into two main groups: initiator and executioner caspases, based on their structure and function. Initiator caspases, such as caspase-8 and caspase-9, become activated through the formation of large protein complexes, which promote dimerization and self-cleavage. Once activated, they initiate the activation of effector caspases, like caspase-3 and caspase-7, which then execute the final stages of programmed cell death. Caspase-2 has similar structure to the initiator caspase-9, particularly due to the presence of a caspase activation and recruitment domain (CARD). Its activation mechanism also involves dimerization, followed by autoprocessing, which is essential for its full activation. Similar to caspase-9 and its role within the apoptosome, the multiprotein complex that facilitates caspase-2 activation has been designated as the "PIDDosome" (Caspase-2-PIDDosome). This structure is formed by the C-terminal fragment of PIDD1 (p53-induced death domain protein 1) and RAIDD (receptor-interacting protein-associated ICH-1/CED-3 homolog with a death domain, also known as CRADD) in a 5:5 stoichiometric ratio. Two additional RAIDD molecules are positioned on top of the core complex, completing its assembly. RAIDD functions as a dual adaptor protein, featuring specialized domains that facilitate key interactions.
Shortly afterwards, the US VII Corps, in full strength and spearheaded by the 2nd Armored Cavalry Regiment, launched an armored attack into Iraq early on 24 February, just to the west of Kuwait, surprising Iraqi forces. Simultaneously, the US XVIII Airborne Corps launched a sweeping "left-hook" attack across southern Iraq's largely undefended desert, led by the US 3rd Armored Cavalry Regiment and the 24th Infantry Division (Mechanized). This movement's left flank was protected by the French Division Daguet. The 101st Airborne Division conducted a combat air assault into enemy territory. The 101st Airborne Division had struck 249 km (155 mi) behind enemy lines. It was the deepest air assault operation in history. Approximately 400 helicopters transported 2,000 soldiers into Iraq where they destroyed Iraqi columns trying to flee westward and prevented the escape of Iraqi forces. The 101st Airborne Division travelled a further 80 to 100 km (50 to 60 mi) into Iraq. By nightfall, the 101st cut off Highway 8 which was a vital supply line running between Basra and the Iraqi forces. The 101st had lost 16 soldiers in action during the 100-hour war and captured thousands of enemy prisoners of war. The French force quickly overcame Iraq's 45th Infantry Division, suffering light casualties and taking a large number of prisoners, and took up blocking positions to prevent an Iraqi counterattack on the coalition's flank. The movement's right flank was protected by the United Kingdom's 1st Armoured Division.
Sources: en.wikipedia.org
Corticosteroids such as prednisolone, deflazacort, and vamorolone (Agamree) lead to short-term improvements in muscle strength and function up to 2 years. Corticosteroids have also been reported to help prolong walking, though the evidence for this is not robust. Disease-specific physical therapy helps maintain muscle strength, flexibility, and function. It aims to: Minimize the development of contractures and deformity by developing a program of stretches and exercises where appropriate Anticipate and minimize other secondary complications of physical nature by recommending bracing and durable medical equipment Monitor respiratory function and advise on techniques to assist with breathing exercises and methods of clearing secretions Orthopedic appliances (such as braces and wheelchairs) may improve mobility and the ability for self-care. Form-fitting removable leg braces that hold the ankle in place during sleep can defer the onset of contractures. Appropriate respiratory support as the disease progresses is important. Cardiac problems may require a pacemaker. The medication eteplirsen, a Morpholino antisense oligo, has been approved in the United States for the treatment of mutations amenable to dystrophin exon 51 skipping. The US approval has been controversial as eteplirsen failed to establish a clinical benefit; it has been refused approval by the European Medicines Agency. The medication ataluren (Translarna) is approved for use in the European Union.
Azidophenylalanine (4-azido-L-phenylalanine) is an unnatural amino acid derivative of L-phenylalanine, featuring an azide group at the para position of the phenyl ring. It is a bioorthogonal click-chemistry reagent that can be genetically incorporated into proteins via expanded genetic code techniques for site-specific labeling and functionalization. The compound serves as a vibrational reporter for local protein environments due to its azide group and is used in photo-crosslinking for protein interaction studies.
After that initial post-mastectomy fat-graft seeding in the operating room, the patient leaves hospital with a slight breast mound that has been seeded to become the foundation tissue matrix for the breast reconstruction. Then, after 3–5 weeks of continual external vacuum expansion of the breast mound (seeded recipient-site) – to promote the histologic regeneration of the extant tissues (fat, glandular) via increased blood circulation to the mastectomy scar (suture site) – the patient formally undergoes the first fat-grafting session for the reconstruction of her breasts. The external vacuum expansion of the breast mound created an adequate, vascularised, breast-tissue matrix to which the autologous fat is injected; and, per the patient, such reconstruction affords almost-normal sensation throughout the breast and the nipple-areola complex. Patient recovery from non-surgical fat graft breast reconstruction permits her to resume normal life activities at 3-days post-procedure.
== Mechanism == At the cellular level, metabolic myopathies lack some kind of enzyme or transport protein that prevents the chemical reactions necessary to create adenosine triphosphate (ATP). ATP is often referred to as the "molecular unit of currency" of intracellular energy transfer. The lack of ATP prevents the muscle cells from being able to function properly. Some people with a metabolic myopathy never develop symptoms due to the body's ability to produce enough ATP through alternative pathways (e.g. the majority of those with AMP-deaminase deficiency are asymptomatic). H2O + ATP → H+ + ADP + Pi + energy → muscle contraction ATP is needed for muscle contraction by two processes:
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.